Hepcinat Plus is a fixed-dose combination tablet developed by Natco Pharma Ltd for the treatment of chronic hepatitis C virus (HCV) infection. This formulation combines two antiviral agents—Sofosbuvir 400 mg and Daclatasvir 60 mg—into a single tablet, simplifying the treatment regimen for patients.
Category | Antiviral drug |
Brand | Natco |
Ingredient | Sofosbuvir |
Prescription Required | Yes |
Strength | 60/400mg |
Package | 28 Tablets |
Hepcinat Plus works by combining two antiviral agents, Sofosbuvir and Daclatasvir, to target different stages of the hepatitis C virus (HCV) lifecycle. Sofosbuvir is a nucleotide polymerase inhibitor that interferes with the viral RNA polymerase, an enzyme essential for the replication of the HCV genome. By blocking this enzyme, sofosbuvir prevents the virus from replicating and producing new viral particles.
Hepcinat Plus offers significant benefits in the treatment of chronic hepatitis C virus (HCV) infection. By combining two potent antiviral agents, Sofosbuvir and Daclatasvir, it provides a highly effective treatment option that targets different stages of the HCV lifecycle. Sofosbuvir inhibits the viral RNA polymerase, preventing the replication of the virus, while Daclatasvir disrupts the NS5A protein, which is essential for viral replication and assembly.
Hepcinat Plus should not be taken by individuals who are allergic to either of its active ingredients, sofosbuvir or daclatasvir, or to any of the tablet’s inactive components. It is also not suitable for people with severe liver impairment or decompensated liver disease unless specifically prescribed and closely monitored by a healthcare provider.
Hepcinat Plus should be taken exactly as prescribed by a healthcare provider. The usual dose is one tablet taken once daily, containing Sofosbuvir 400 mg and Daclatasvir 60 mg, and it can be taken with or without food. It is important to take the medication at the same time each day to maintain consistent levels in the bloodstream.
There are no reviews yet.